Mesoblast Limited (ASX: MSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mesoblast Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Mesoblast Limited (ASX: MSB)
    Latest News

    2 street signs with winner and loser COVID recovery oil price
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a happy end to the trading week today.

    Read more »

    Smiling man sits in front of a graph on computer while using his mobile phone.
    Broker Notes

    Leading brokers name 3 ASX shares to buy today

    Here's why brokers believe that now could be the time to snap up these shares.

    Read more »

    Arrows pointing upwards with a man pointing his finger at one.
    Healthcare Shares

    Why Mesoblast shares could rocket 60% higher

    Let's see why Bell Potter is tipping this stock as a buy right now.

    Read more »

    A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
    Share Fallers

    Why Lynas, Mesoblast, PEXA, and Sayona Mining shares are tumbling today

    These shares are ending the week in the red. But why?

    Read more »

    A man flies into the sky over a city building-scape with a rocket jet pack sketched onto his back representing the Imugene share price skyrocketing today
    Healthcare Shares

    A $115 million growth opportunity!? Is this ASX 200 stock about to skyrocket?

    The company's share price has jumped 141.67% over the past 12 months.

    Read more »

    a person stands arms outstretched on the top of a mountain with a beautiful sunrise in the sky
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Investors sent the ASX 200 into higher uncharted territory today.

    Read more »

    A happy investor sits at his desk in front of his laptop and does the mexican wave with his arms to celebrate the returns from his ASX dividend shares
    Record Highs

    Oops, the ASX 200 did it again! Another record high

    The ASX 200 reset its record high for the third time in a week and a slew of stocks and…

    Read more »

    Fast businessman with a car wins against the competitors.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was another day, another record high for ASX shares.

    Read more »

    Wife and husband with a laptop on a sofa over the moon at good news.
    Healthcare Shares

    Heres what $1k invested in Mesoblast shares a month ago is worth now

    This stock has exploded in the last month.

    Read more »

    A woman looks quizzical while looking at a dollar sign in the air.
    Share Gainers

    After 50% or more share price growth, should you sell these ASX 200 winners?

    These stocks wowed investors with their magnificent share price growth in FY25. What now?

    Read more »

    A group of businesspeople clapping.
    Share Gainers

    These were the best performing ASX 200 shares in July

    Let's see why these shares smashed the market last month.

    Read more »

    Man smiling at a laptop because of a rising share price.
    Broker Notes

    4 ASX shares to buy this week: experts

    Looking for investment inspiration?

    Read more »

    Frequently Asked Questions

    No, Mesoblast does not pay shareholder dividends at this time.

    Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.

    Mesoblast Ltd listed on the ASX on 16 December 2004.

    MSB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mesoblast Limited

    Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.

    Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines. 

    Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).

    Profile

    since

    Note